Identification of mCMQ069, a novel antimalarial with potential for a single-dose cure and/or 28-day chemoprevention

  • bioRxiv. 2024 Jul 1:2024.07.01.601566. doi: 10.1101/2024.07.01.601566.
Anil K Gupta ,  James Pedroarena ,  Armen Nazarian ,  Jenya Antonova-Koch ,  Frank Weiss ,  Krittikorn Kumpornsin ,  Victor Chi ,  Ashley K Woods ,  Kyoung-Jin Lee ,  Sean B Joseph ,  Shuangwei Li ,  Jason Brittain ,  Eugenio De Hostos ,  James Duffy ,  Anne Cooper ,  Peter G Schultz ,  Case W McNamara ,  Arnab K Chatterjee
PMID: 39005341 DOI: 10.1101/2024.07.01.601566
Abstract

In efforts towards eliminating malaria, a discovery program was initiated to identify a novel antimalarial using KAF156 as a starting point. Following the most recent TCP/TPP guidelines, we have identified mCMQ069 with a predicted single oral dose for treatment (∼40-106 mg) and one-month chemoprevention (∼96-216 mg). We have improved unbound MPC and predicted human clearance by 18-fold and 10-fold respectively when compared to KAF156.

Products